Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
for
Gastric or Gastroesophageal Junction Adenocarcinoma,
Location: Fairfax VA, Durham NC, Pittsburgh PA, Louisville KY,